M. Tang

发表

Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat

Junlan Chuan, M. Tang, Chan Zhu, 2021, Frontiers in Pharmacology.

Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germlineBRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

A. Italiano, S. Domchek, S. Im, 2019, Poster Discussion Abstracts.

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.

Y. Bang, S. Domchek, B. Kaufman, 2019, Journal of Clinical Oncology.

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

M. Gore, Y. Drew, S. Domchek, 2018, Gynecologic Oncology.

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

D. Gibbons, M. Roudier, Dong-Wan Kim, 2020, British Journal of Cancer.

Improving sleep quality for cancer patients: benefits of a home-based exercise intervention

T. Liou, M. Tang, Chia-chin Lin, 2010, Supportive Care in Cancer.

Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.

M. Edelman, B. Seal, A. Davidoff, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.

M. Edelman, B. Seal, A. Davidoff, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations.

D. Gibbons, M. Roudier, M. Marotti, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.